-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Pasithea Therapeutics, Raises Price Target to $4

Benzinga·11/13/2026 18:15:42
Listen to the news
HC Wainwright & Co. analyst Sara Nik maintains Pasithea Therapeutics (NASDAQ:KTTA) with a Buy and raises the price target from $3 to $4.